Key Takeaways:
Intuitive Surgical Inc. is scheduled to report second-quarter earnings after the closing bell Thursday, with analysts expecting the robotic surgery leader to post $2.50 a share in earnings on $2.82 billion in revenue.
The Sunnyvale, California-based company's results will test whether demand for its da Vinci surgical systems is holding up as Wall Street recalibrates expectations. Analysts have been trimming price targets in recent weeks even as they maintain largely bullish ratings.
"The bar is set for another solid quarter from Intuitive, but the guidance will matter more than the print," BMO Capital analyst Vik Chopra, who rates the stock Outperform with a $518 price target, said.
Consensus estimates call for revenue of $2.82 billion, up 15.6% from $2.44 billion a year earlier. Earnings per share of $2.50 would represent a 14.2% increase from $2.19 in the year-ago period. The company did not provide preliminary guidance.
Analysts have been revising their models ahead of the print. Evercore ISI's Vijay Kumar maintained an In-Line rating while cutting his price target to $430 from $480 on July 6. Bank of America's Travis Steed kept a Buy rating but lowered his target to $520 from $650 in May. Barclays' Matt Miksic trimmed his Overweight target to $651 from $712 in April, while Leerink Partners' Mike Kratky cut his Outperform target to $573 from $622.
The stock closed Friday at $406.78, implying roughly 27% upside to the average analyst price target of about $538. Shares have declined about 12% this year, underperforming the S&P 500's gain of about 8%.
Intuitive Surgical dominates the surgical robotics market with more than 9,500 da Vinci systems installed globally. The company's procedure volume growth — a key metric investors track — has historically driven recurring revenue from instruments and accessories. In May, the company promoted Taylor Patton, its global senior vice president of the endoluminal business, to chief commercial and marketing officer.
The earnings report comes as the broader medical device sector faces pressure from hospital budget constraints and regulatory scrutiny. Intuitive's competitive position faces a potential challenge from Johnson & Johnson's Ottava surgical robot platform, which remains in development.
The Q2 results will signal whether procedure volumes are accelerating and whether the company can sustain its premium valuation. Investors will watch Thursday's call for any update on the Ion endoluminal system adoption and international expansion plans.
This article is for informational purposes only and does not constitute investment advice.
